Antibe Therapeutics increases previously announced non-brokered personal positioning to up to $5,000,000 Antibe Therapeutics Inc. is pleased to announce, based on improved inbound demand, that the previously announced non-brokered private placement has been increased to up to $5,000,000 on the same conditions and terms as announced in Antibe's press release dated March 21, 2014. Related StoriesExpanded use for IntelliCap with additional CE Mark for aspiration of fluidsLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman The Offering is likely to close in one or more closings, with the initial closing expected on March 31, 2014, subject to TSXV approval, also to the fulfillment of customary closing circumstances.Richard A. Gephardt; President and CEO, Gephardt Federal government AffairsThe Hon. Billy Tauzin; President and CEO, PhRMADavid Brennan; Chairman and CEO, AstraZenecaDavid B. Snow, Jr.; Chairman and CEO, MedcoRelated StoriesNew initiative released to accelerate seek out effective HIV vaccineGHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengueNew research might offer approaches for developing toxoplasma-inactivated vaccinePanel discussions will consider important elements of the bill authored by Senate Finance Committee Chairman Max Baucus, that your committee is scheduled to vote on Tuesday; the payoff associated with medical reform and analysis; and comparative effectiveness. The other major theme of the day may be the public health battle against H1N1, with two classes, titled Pressure on the System: Swine Flu and the general public Health Response and Vaccine Wars: Doctors vs.